Article Sidebar
DOI:
10.4314/tjpr.v11i1.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Development and Targeting Efficiency of Irinotecan Engineered Proniosomes
Abstract
Purpose: This study is aimed at achieving improvement in the efficacy, reduced toxicity and enhancement of therapeutic index of irinotecan.
Methods: Proniosomes of irinotecan hydrochloride trihydrate were prepared by slurry method using different surfactants, cholesterol and dicetyl phosphate. The formulations were then characterized with respect to shape, surface morphology, entrapment efficiency, in vitro drug release, in vivo drug targeting and stability.
Results: The proniosomes were smooth in texture indicating, thin and uniform coating over maltodextrin powder. The highest entrapment efficiency was found for formulation F2 (74.9 ± 2.7 %). The highest cumulative drug release in 24 h was achieved with formulation F3 (98.2 %) In vivo results for the proniosomes reveal that the drug was preferentially targeted to liver followed by lung and spleen. Stability studies indicate that 4 ºC was the most suitable condition for the storage of formulation F2.
Conclusion: Proniosomes offer a suitable alternative colloidal carrier approach to achieving drug targeting. Proniosomes containing irinotecan are retained at targeted sites and are capable of releasing drug for an extended period of time.
Keywords: Irinotecan, proniosomes, Drug targeting, In vivo tissue distribution, Stability studies.
